UBS raised the firm’s price target on Universal Health to $177 from $152 and keeps a Neutral rating on the shares. Universal Health’s Q4 adjusted EPS was ahead of consensus by $8M, partly due to $18M of supplemental payments not included in many estimates, the analyst tells investors in a research note. Guidance anticipates some moderation in acute volume growth, offset by improved pricing growth due to expectations of higher acuity as well as favorable reimbursementtrends, UBS says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on UHS:
- UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS AND 2024 OPERATING RESULTS FORECAST
- Universal Health sees FY24 CapEx $850M-$1B
- Universal Health sees FY24 adjusted EPS $13.00-$14.00, consensus $11.75
- Universal Health reports Q4 adjusted EPS $3.13, consensus $2.88
- Notable companies reporting after market close
